Can one company disrupt the entire lab industry? 23andMe seems determined to find out. The Mountain View, California-based personal genomics and biotechnology company, which first marketed its … [Read more...]
Genetics Update: 23andMe Seeks to Upend the Medical Industry via Genetic Testing Information Sharing
Upfront Next-Generation Sequencing for Lung Cancer Patients Saves Time, Money
Use of upfront next-generation sequencing (NGS) testing at diagnosis of patients with metastatic non-small-cell lung cancer (mNSCLC) is associated with substantial cost savings, according to a study … [Read more...]
Guidelines at a Glance
Screening for HIV Published June 11 in the Journal of the American Medical Association. The U.S. Preventive Services Task Force (USPSTF) recommends screening for HIV infection in adolescents and … [Read more...]
Preventive Genomic Screening In Young Adults Highly Cost Effective
A new model shows that universal preventive genomic screening for multiple conditions in early adulthood could be highly cost-effective in a single-payer health care system, according to a study … [Read more...]
Study Showing PGx Testing Improves Depression Outcomes, Key to Myriad’s Reimbursement Strategy
Pharmacogenomic testing (PGx) provides clinically meaningful improvement in response and remission rates for difficult-to-treat depression patients over standard of care, according to a study … [Read more...]
Payer Medical Policies Can Promote Effective Use of Comprehensive Sequencing In Community Oncology Setting
Comprehensive genomic profiling (CGP) identifies clinically relevant genomic alterations that can be used to inform treatment decisions in community-based oncology practices that benefit both patients … [Read more...]
Zika Blood Screening Not Cost-Effective, Study Finds
Screening blood donors for Zika virus is not cost-effective in the United States or Puerto Rico, according to a study published Jan. 8 in the Annals of Internal Medicine. Despite U.S. Food and Drug … [Read more...]